A study led by researchers at the University of Arizona Health Sciences reveals that prior vaccination against the original SARS-CoV-2 strain did not impair the immune system’s ability to combat Delta and Omicron variants, despite a slight dip in mutation-specific antibody production. Published in Nature Immunology, the findings could guide future vaccine development and booster strategies.
The research team compared antibody responses in vaccinated and unvaccinated individuals infected with Delta or Omicron. They discovered that vaccinated individuals produced significantly higher overall antibody levels against these variants than their unvaccinated counterparts. However, the production of Delta-specific antibodies was partially reduced in vaccinated people, a phenomenon linked to “antigenic imprinting”—where prior immunity slightly suppresses new responses to viral mutations.
Dr. Deepta Bhattacharya, the study’s lead author, explained, “Vaccinated people still mounted strong protective responses, especially targeting unchanged parts of the virus.” Surprisingly, even unvaccinated individuals infected with Delta or Omicron for the first time generated weak antibody responses to the mutated portions of the virus, highlighting the challenges of natural immunity against evolving strains.
“If researchers can identify which viral parts evade immunity, we could design vaccines to broaden protection against future mutations,” Bhattacharya added.
The study underscores the resilience of vaccine-induced immunity while pointing to opportunities for improving vaccine design. Future research will explore ways to minimize immune suppression effects and optimize booster timing, potentially enhancing long-term protection against emerging variants.
Add comment